GeneDx Cuts Full-Year Revenue Guidance by Over 12%, Reports Q1 Adjusted Net Loss
Summary
GeneDx Holdings Corp. reported first-quarter results with a significant year-over-year increase in exome and genome testing volume, but lowered its full-year 2026 revenue guidance by over 12% and reported an adjusted net loss for the quarter.
Key Events
-
Q1 Financial Performance
Revenue grew 17% year-over-year to $102.3 million, driven by a 34% increase in exome and genome test volume. However, the company reported an adjusted net loss of $8.2 million, a decline from an adjusted net income of $9.2 million in Q1 2025.
-
Significant Guidance Reduction
Full-year 2026 revenue guidance was lowered to $475-$490 million from the previous $540-$555 million, representing a cut of over 12%. Exome and genome revenue growth guidance was also reduced.
-
Shift to Adjusted Net Loss Outlook
The company now expects an adjusted net loss of approximately $5 million for Q2 2026, indicating a more challenging profitability outlook in the near term.
-
Impairment Loss
GAAP net loss for Q1 2026 included a $31.3 million impairment loss.
Analysis
This 8-K filing contains highly negative news for GeneDx investors, primarily due to the substantial reduction in full-year revenue guidance. The company's updated outlook now projects revenue to be over 12% lower than previously expected, signaling a significant slowdown or increased headwinds. The shift from an adjusted net income in the prior year to an adjusted net loss in Q1 2026, coupled with a projected adjusted net loss for Q2, raises concerns about the company's path to profitability despite strong volume growth in its core exome and genome testing. The $31.3 million impairment loss further contributes to the GAAP net loss. Investors will likely react negatively to the revised outlook, especially given the stock is already trading near its 52-week low. The company's ability to manage its cash burn and achieve its revised profitability targets will be critical to monitor.
At the time of this filing, WGS was trading at $46.12 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2B. The 52-week trading range was $55.17 to $170.87. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.